Add-on Acquisition • Life Science

Emalex Biosciences Acquires Psyadon Pharmaceuticals

On August 14, 2018, Emalex Biosciences acquired life science company Psyadon Pharmaceuticals

Acquisition Context

This is Emalex Biosciences’ 1st transaction in the Life Science sector.
This is Emalex Biosciences’ 1st transaction in the United States.
This is Emalex Biosciences’ 1st transaction in Maryland.

Explore All 3110 Add-on Acquisition Life Science Deals - Search the Database Free

M&A Deal Summary
Date	August 14, 2018
Target	Psyadon Pharmaceuticals
Sector	Life Science
Buyer(s)	Emalex Biosciences
Deal Type	Add-on Acquisition

Target Company

Psyadon Pharmaceuticals

Germantown, Maryland, United States

Psyadon Pharmaceuticals, Inc. is a developer, register and marketer of an ecopipam, a new chemical entity with orphan drug designation for the treatment of pediatric Tourette Syndrome (TS) in patients under 16 years of age.

Explore More Deals

Browse All 215,158 Deals

FILTER BY

Buyer Type (PE or Strategic)
Deal Size ($10M to $10B+)
Sector (60 Sectors)
Deal Type
Geography
& More

Search Free

Buyer Overview 1

Buyer

Emalex Biosciences

Northbrook, Illinois, United States

Category	Company
Sector	Life Science

DESCRIPTION

Emalex Biosciences, Inc. is a biopharmaceutical company dedicated to the development of new treatments for rare and orphan neurological conditions. Ecopipam, its first development candidate, is a novel compound that has been studied as a potential treatment for many central nervous system (CNS) disorders, including pediatric Tourette Syndrome.

Deal Context for Buyer	#
Overall	1 of 1
Sector: Life Science	1 of 1
Type: Add-on Acquisition	1 of 1
State: Maryland	1 of 1
Country: United States	1 of 1
Year: 2018	1 of 1

Explore Related M&A Activity

Life Science M&A - Add-on Acquisition M&A Deals - Maryland M&A - United States M&A - 2018 M&A